Devyser Diagnostics AB has been awarded a tender for Devyser?s CFTR fragment analysis products, that are used for screening and confirmation of cystic fibrosis. The tender with the University Hospital in Verona is valid for a period of twelve months. Indicative order value is estimated to amount to approximately SEK 1.5 million .
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
99 SEK | +5.77% | +0.20% | +25.95% |
05-08 | Transcript : Devyser Diagnostics AB, Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Devyser Diagnostics AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.95% | 148M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- DVYSR Stock
- News Devyser Diagnostics AB
- Devyser Diagnostics AB Wins Tender for Cystic Fibrosis in Italy